Abbott Laboratories

Revenue declined +8.1% YoY to $40.11B. Net margin at 14.27% (expanding ▲). Return on equity 12.01%, ROA 7.03%, ROIC 10.48%.

• Revenue declined +8.1% YoY to $40.11B.
• Net margin at 14.27% (expanding ▲).
• Return on equity 12.01%, ROA 7.03%, ROIC 10.48%.
• Gross margin 0.00%, operating margin 16.15%.
• Free cash flow margin 12.61% ($5.06B).
• Net income down ▼ +17.5% YoY.
• Debt/equity 0.25, current ratio 1.39, net debt $6.13B.
• Asset turnover 0.36 — capital efficiency.

Latest annual report (10-K) filed Feb 20, 2026. Latest quarterly report (10-Q) filed Apr 29, 2026. 14 recent 8-K material-event filings in the index.

• Latest annual report (10-K) filed Feb 20, 2026.
• Latest quarterly report (10-Q) filed Apr 29, 2026.
• 14 recent 8-K material-event filings in the index.
• Recent insider Form 4s: 0 buy vs 0 sell transactions.
• ~10,000+ recent 13F-HR filings reference Abbott Laboratories; broad institutional reporting.
• Recent filers include THURSTON, SPRINGER, MILLER, HERD & TITAK, INC., LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
• 8 recent 13D activist/beneficial-ownership filings — potential catalyst.
• 12 recent 13G passive institutional ownership notices.

5 risk signal(s), 2 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. Revenue grew -8.1% but receivables grew +5.5% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.

• Receivables outpacing revenue: Accounts receivable grew +5.5% YoY vs revenue growth of -8.1%. The +13.6% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
• Free cash flow deteriorating: FCF declined +35.2% YoY (from $7.80B to $5.06B). With OCF at $7.26B and capex at $2.20B, cash generation capacity is weakening — monitor for dividend/buyback sustainability.
• NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 4 filing(s).
• Material weakness in internal controls: The term "material weakness" appears in 20 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
• NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
• Operating cash flow exceeds net income: OCF is 1.27x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
• Endogenous analysis: Revenue grew -8.1% but receivables grew +5.5% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
• Endogenous analysis: Free cash flow declined despite stable or rising capex, indicating the cash burn is operational rather than investment-driven. This is a structural concern — cost reduction or asset sales may be needed to restore FCF.
• Endogenous analysis: The combination of explicit "going concern" language in the filing with deteriorating cash flow or rising leverage is a severe warning signal — the company's own auditors have flagged doubt about the ability to continue as a going concern.
• 2 new XBRL disclosure(s) in latest filing — expanding reporting scope.
• 20 disclosure(s) dropped from prior year — reduced reporting granularity.
• 2 new risk-language term(s) detected in filing text: Going concern doubt, Restatement of financial statements.
• Ongoing high-severity risk language: Material weakness in internal controls.